Beam Therapeutics Inc. (BEAM) Social Stream



Beam Therapeutics Inc. (BEAM): $45.56

-0.93 (-2.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BEAM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 401

in industry

Beam Therapeutics Inc (BEAM) Price Targets From Analysts

Use the tables below to see what analysts covering Beam Therapeutics Inc think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-09 10 $150 $85 $124.333 $57.3 116.99%
2021-12-22 10 $150 $85 $121.555 $57.3 112.14%
2022-01-05 11 $150 $85 $122.4 $57.3 113.61%
2022-01-10 11 $159 $85 $124.5 $57.3 117.28%
2022-02-01 10 $159 $85 $124.5 $57.3 117.28%
2022-02-28 10 $159 $85 $126.25 $57.3 120.33%
2022-03-01 9 $154 $85 $124.625 $57.3 117.5%

The Trend in the Analyst Price Target


Over the past 38 weeks, BEAM's average price target has gone up $30.95.

BEAM reports an average of 35.97% for its upside potential over the past 47 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-04-03 6 145 84 108.00 79.74 35.44%
2021-04-10 6 145 84 108.00 70.23 53.78%
2021-06-05 8 145 62 93.67 82.61 13.39%
2021-06-13 8 145 62 93.67 88.76 5.53%
2021-06-26 8 145 62 93.67 93.85 -0.19%

BEAM Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.44 7 0 2 0 0 9

The Trend in the Broker Recommendations


BEAM's average broker recommendation rating improved by 0.68 over the prior 43 weeks.

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • BEAM has a greater average analyst price target than 1070.88% of stocks in the mid market cap category.
  • BEAM has a greater upside potential (average analyst target price relative to current price) than 986.34% of stocks in the mid market cap category.
  • Beam Therapeutics Inc's number of analysts covering the stock is higher than 967.08% of Pharmaceutical Products stocks.
  • BEAM has a lower variance in analysts' estimates than -760.67% of stocks in the mid market cap category.

In the Pharmaceutical Products industry, BCRX, BCAB, and ALVR are the three stocks most similar to Beam Therapeutics Inc regarding the price target and analyst recommendation information presented here.

Make investment decisions regarding BEAM using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.547 seconds.